Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
INTEGRATED BIOPHARMA INC
Report date June 30, 2023 · Filed November 16, 2023
Section 16 reporting ended · disclosed 2023-11-16. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-03-20 transaction · row 1
1 source rowRow 1 · 2023-03-20 · Other · Disposed 4,299,533 · Balance 0 |
| Common StockSEC Table I · non-derivative | IndirectAs sole member of LLC or Trustee of Trusts | 0 |
Reported balance
After 2023-03-20 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2023-03-20 · Other · Disposed 853,022 · Balance 0 F1: Includes (i) 819,628 shares registered to the name of EGK LLC, an entity the Reporting Person was the sole member of and (ii) 16,697 shares held in each of the Riva Grantor Trust and Christina Kay Grantor Trust whereas the Reporting Person was the Trustee. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.23 · Expires 2024-03-20 | Direct | 0 |
Reported balance
After 2023-03-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-03-20 · Other · Disposed 150,000 · Balance 0 F2: The option vested over three years beginning of the first year anniversary noted herein. F3: Due to the passing of the Reporting Person, the Expiration Date is one year from the date of death. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.72 · Expires 2024-03-20 | Direct | 0 |
Reported balance
After 2023-03-20 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-03-20 · Other · Disposed 100,000 · Balance 0 F4: Includes 33,333 shares that were not vested at the time of the Reporting Person's passing. F2: The option vested over three years beginning of the first year anniversary noted herein. F3: Due to the passing of the Reporting Person, the Expiration Date is one year from the date of death. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.05 · Expires 2024-03-20 | Direct | 0 |
Reported balance
After 2023-03-20 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-03-20 · Other · Disposed 65,000 · Balance 0 F5: Includes 43,333 shares that were not vested at the time of the Reporting Person's passing. F2: The option vested over three years beginning of the first year anniversary noted herein. F3: Due to the passing of the Reporting Person, the Expiration Date is one year from the date of death. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.45 · Expires 2023-03-20 | Direct | 0 |
Reported balance
After 2023-03-20 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-03-20 · Other · Disposed 100,000 · Balance 0 F6: None of the Options were vested at the time of passing of the Reporting Person. F2: The option vested over three years beginning of the first year anniversary noted herein. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes (i) 819,628 shares registered to the name of EGK LLC, an entity the Reporting Person was the sole member of and (ii) 16,697 shares held in each of the Riva Grantor Trust and Christina Kay Grantor Trust whereas the Reporting Person was the Trustee.
F2: The option vested over three years beginning of the first year anniversary noted herein.
F3: Due to the passing of the Reporting Person, the Expiration Date is one year from the date of death.
F4: Includes 33,333 shares that were not vested at the time of the Reporting Person's passing.
F5: Includes 43,333 shares that were not vested at the time of the Reporting Person's passing.
F6: None of the Options were vested at the time of passing of the Reporting Person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 20, 2023 Filed Nov 16, 2023 21:13 UTC | INTEGRATED BIOPHARMA INC INBP · Entity 8227 | OtherStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $0.45 | $0.00 |
DisclosureSEC source: 0001345281-23-000006 · primary_doc.xml · derivative · entry 6 KAY E GERALD · CIK 0001053310 · Director · Executive Chairman & President · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2023-03-20 F6 · shares: None of the Options were vested at the time of passing of the Reporting Person. F2 · derivative.exercise_date: The option vested over three years beginning of the first year anniversary noted herein. F6 · derivative.expiration_date: None of the Options were vested at the time of passing of the Reporting Person. F6 · derivative.underlying_shares: None of the Options were vested at the time of passing of the Reporting Person. Read SEC document |
| March 20, 2023 Filed Nov 16, 2023 21:13 UTC | INTEGRATED BIOPHARMA INC INBP · Entity 8227 | OtherStock Option (right to buy) · Derivative | 65,000 | $0.00 Strike: $1.05 | $0.00 |
DisclosureSEC source: 0001345281-23-000006 · primary_doc.xml · derivative · entry 5 KAY E GERALD · CIK 0001053310 · Director · Executive Chairman & President · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 65,000 shares Expires 2024-03-20 F5 · shares: Includes 43,333 shares that were not vested at the time of the Reporting Person's passing. F2 · derivative.exercise_date: The option vested over three years beginning of the first year anniversary noted herein. F3 · derivative.expiration_date: Due to the passing of the Reporting Person, the Expiration Date is one year from the date of death. F5 · derivative.underlying_shares: Includes 43,333 shares that were not vested at the time of the Reporting Person's passing. Read SEC document |
| March 20, 2023 Filed Nov 16, 2023 21:13 UTC | INTEGRATED BIOPHARMA INC INBP · Entity 8227 | OtherStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $0.72 | $0.00 |
DisclosureSEC source: 0001345281-23-000006 · primary_doc.xml · derivative · entry 4 KAY E GERALD · CIK 0001053310 · Director · Executive Chairman & President · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2024-03-20 F4 · shares: Includes 33,333 shares that were not vested at the time of the Reporting Person's passing. F2 · derivative.exercise_date: The option vested over three years beginning of the first year anniversary noted herein. F3 · derivative.expiration_date: Due to the passing of the Reporting Person, the Expiration Date is one year from the date of death. F4 · derivative.underlying_shares: Includes 33,333 shares that were not vested at the time of the Reporting Person's passing. Read SEC document |
| March 20, 2023 Filed Nov 16, 2023 21:13 UTC | INTEGRATED BIOPHARMA INC INBP · Entity 8227 | OtherStock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $0.23 | $0.00 |
DisclosureSEC source: 0001345281-23-000006 · primary_doc.xml · derivative · entry 3 KAY E GERALD · CIK 0001053310 · Director · Executive Chairman & President · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 150,000 shares Expires 2024-03-20 F2 · derivative.exercise_date: The option vested over three years beginning of the first year anniversary noted herein. F3 · derivative.expiration_date: Due to the passing of the Reporting Person, the Expiration Date is one year from the date of death. Read SEC document |
| March 20, 2023 Filed Nov 16, 2023 21:13 UTC | INTEGRATED BIOPHARMA INC INBP · Entity 8227 | OtherCommon Stock | 853,022 | $0.00 | $0.00 |
DisclosureSEC source: 0001345281-23-000006 · primary_doc.xml · nonDerivative · entry 2 KAY E GERALD · CIK 0001053310 · Director · Executive Chairman & President · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · As sole member of LLC or Trustee of Trusts Disclosed balance after: 0 F1 · shares: Includes (i) 819,628 shares registered to the name of EGK LLC, an entity the Reporting Person was the sole member of and (ii) 16,697 shares held in each of the Riva Grantor Trust and Christina Kay Grantor Trust whereas the Reporting Person was the Trustee. F1 · ownership.nature: Includes (i) 819,628 shares registered to the name of EGK LLC, an entity the Reporting Person was the sole member of and (ii) 16,697 shares held in each of the Riva Grantor Trust and Christina Kay Grantor Trust whereas the Reporting Person was the Trustee. Read SEC document |
| March 20, 2023 Filed Nov 16, 2023 21:13 UTC | INTEGRATED BIOPHARMA INC INBP · Entity 8227 | OtherCommon Stock | 4,299,533 | $0.00 | $0.00 |
DisclosureSEC source: 0001345281-23-000006 · primary_doc.xml · nonDerivative · entry 1 KAY E GERALD · CIK 0001053310 · Director · Executive Chairman & President · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Read SEC document |
| November 09, 2022 Filed Nov 10, 2022 23:39 UTC | INTEGRATED BIOPHARMA INC inbp · Entity 8227 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001053310-22-000003 · primary_doc.xml · derivative · entry 1 KAY E GERALD · CIK 0001053310 · Director · Executive Chairman & President · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2027-11-09 F1 · derivative.exercise_price: The Exercise Price of the Stock Option will be 110% the closing prices of the Issuer's Common Stock on the fifth trading day after the filing of the Issuer's Quarterly Report on Form 10-Q for the period ended September 30, 2022, with the Securities and Exchange Commission. F2 · derivative.exercise_date: The option vests and becomes exercisable in three equal annual installments with the first installment vesting on November 9, 2023. Read SEC document |
| May 06, 2022 Filed May 6, 2022 21:08 UTC | INTEGRATED BIOPHARMA INC inbp · Entity 8227 | GrantCommon Stock | 100,000 | $0.23 | $23,000.00 |
DisclosureSEC source: 0001053310-22-000001 · primary_doc.xml · nonDerivative · entry 1 KAY E GERALD · CIK 0001053310 · Director · Executive Chairman & President · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,345,889 F1 · kind: 100,000 common stock shares acquired upon exercise of stock option grant dated May 24, 2019. Read SEC document |
| May 06, 2022 Filed May 11, 2022 18:37 UTC Amendment | INTEGRATED BIOPHARMA INC inbp · Entity 8227 | Exercise / conversionStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $0.23 | $0.00 |
DisclosureSEC source: 0001053310-22-000002 · primary_doc.xml · derivative · entry 2 KAY E GERALD · CIK 0001053310 · Director · Executive Chairman & President · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 100,000 shares Expires 2024-05-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested 50% (125,000) on grant date (May 24, 2019) and in three equal annual installments for the remaining 50% (125,000) beginning on May 24, 2020 and ending May 24, 2022. Read SEC document |
| May 06, 2022 Filed May 11, 2022 18:37 UTC Amendment | INTEGRATED BIOPHARMA INC inbp · Entity 8227 | Exercise / conversionCommon Stock | 100,000 | $0.23 | $23,000.00 |
DisclosureSEC source: 0001053310-22-000002 · primary_doc.xml · nonDerivative · entry 1 KAY E GERALD · CIK 0001053310 · Director · Executive Chairman & President · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,345,889 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This Form 4 is being amended to correct the Transaction Code in Table 1 and to include the previously inadvertently omitted disclosure in Table II. F2 · security: 100,000 common stock shares acquired upon exercise of stock option grant dated May 24, 2019. Read SEC document |
| November 03, 2021 Filed Nov 4, 2021 14:52 UTC | INTEGRATED BIOPHARMA INC inbp · Entity 8227 | GrantStock Option (right to buy) · Derivative | 65,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001053310-21-000001 · primary_doc.xml · derivative · entry 1 KAY E GERALD · CIK 0001053310 · Director · Executive Chairman & President · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2026-11-03 F1 · derivative.exercise_price: The Exercise Price of the Stock Option will be 110% of the closing price of the Issuer's Common Stock five trading days after the filing of the Issuer's Quarterly Report on Form 10-Q for the period ended September 30, 2021, with the Securities and Exchange Commission. F2 · derivative.exercise_date: The option vests and becomes exercisable in three equal annual installments with the first installment vesting on November 3, 2022. Read SEC document |
| November 04, 2020 Filed Nov 20, 2020 22:13 UTC | INTEGRATED BIOPHARMA INC inbp · Entity 8227 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $0.72 | $0.00 |
DisclosureSEC source: 0001345281-20-000007 · primary_doc.xml · derivative · entry 1 KAY E GERALD · CIK 0001053310 · Director · Executive Chairman & President · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2025-11-04 F1 · derivative.exercise_date: The option vests in three equal annual installments beginning on November 4, 2021. Read SEC document |
| May 24, 2019 Filed May 29, 2019 20:49 UTC | INTEGRATED BIOPHARMA INC inbp.ob · Entity 8227 | GrantStock Option (right to buy) · Derivative | 250,000 | $0.00 Strike: $0.23 | $0.00 |
DisclosureSEC source: 0001053310-19-000001 · primary_doc.xml · derivative · entry 1 KAY E GERALD · CIK 0001053310 · Director · Executive Chairman & President · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2024-05-24 F1 · derivative.exercise_date: The option vests 50% (125,000) on grant date (May 24, 2019) and in three equal annual installments for the remaining 50% (125,000) beginning on May 24, 2020. Read SEC document |
| December 19, 2018 Filed Dec 19, 2018 23:45 UTC | INTEGRATED BIOPHARMA INC inbp.ob · Entity 8227 | GrantCommon Stock | 100,000 | $0.10 | $10,000.00 |
DisclosureSEC source: 0001053310-18-000001 · primary_doc.xml · nonDerivative · entry 1 KAY E GERALD · CIK 0001053310 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,262,556 F1 · kind: 100,000 common stock shares acquired upon exercise of stock option grant dated June 2, 2015. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.